Cite
HARVARD Citation
Swords, R. et al. (n.d.). Corrigendum to "KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study" [Leuk. Res. 50 (Nov) (2016) 123–131. PubMed PMID: 27736729]. Leukemia research. pp. 65-. [Online].